45 related articles for article (PubMed ID: 38589857)
21. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
22. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY;
Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Haddad RI; Harrington K; Tahara M; Ferris RL; Gillison M; Fayette J; Daste A; Koralewski P; Zurawski B; Taberna M; Saba NF; Mak M; Kawecki A; Girotto G; Alvarez Avitia MA; Even C; Toledo JGR; Guminski A; Müller-Richter U; Kiyota N; Roberts M; Khan TA; Miller-Moslin K; Wei L; Argiris A
J Clin Oncol; 2023 Apr; 41(12):2166-2180. PubMed ID: 36473143
[TBL] [Abstract][Full Text] [Related]
24. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Harrington KJ; Burtness B; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Brana I; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesia R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Lin J; Gumuscu B; Swaby RF; Rischin D
J Clin Oncol; 2023 Feb; 41(4):790-802. PubMed ID: 36219809
[TBL] [Abstract][Full Text] [Related]
25. Immune-related adverse events and the balancing act of immunotherapy.
Conroy M; Naidoo J
Nat Commun; 2022 Jan; 13(1):392. PubMed ID: 35046403
[TBL] [Abstract][Full Text] [Related]
26. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
Foster CC; Couey MA; Kochanny SE; Khattri A; Acharya RK; Tan YC; Brisson RJ; Leidner RS; Seiwert TY
Cancer; 2021 Dec; 127(24):4565-4573. PubMed ID: 34547103
[TBL] [Abstract][Full Text] [Related]
27. Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era.
Botticelli A; Pomati G; Cirillo A; Mammone G; Ciurluini F; Cerbelli B; Sciattella P; Ralli M; Romeo U; De Felice F; Catalano C; Vullo F; Della Monaca M; Amirhassankhani S; Tomao S; Valentini V; De Vincentiis M; Tombolini V; Della Rocca C; Polimeni A; di Gioia C; Corsi A; D'Amati G; Mezi S; Marchetti P
J Transl Med; 2021 Jul; 19(1):303. PubMed ID: 34253248
[TBL] [Abstract][Full Text] [Related]
28. Immortal Time Bias in Observational Studies.
Yadav K; Lewis RJ
JAMA; 2021 Feb; 325(7):686-687. PubMed ID: 33591334
[No Abstract] [Full Text] [Related]
29. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Machiels JP; René Leemans C; Golusinski W; Grau C; Licitra L; Gregoire V; ; ;
Ann Oncol; 2020 Nov; 31(11):1462-1475. PubMed ID: 33239190
[No Abstract] [Full Text] [Related]
30. Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors.
Dall'Olio FG; Di Nunno V; Massari F
J Clin Oncol; 2020 Jan; 38(1):105-106. PubMed ID: 31675246
[No Abstract] [Full Text] [Related]
31. Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice.
Szturz P; Bossi P; Vermorken JB
Curr Opin Otolaryngol Head Neck Surg; 2019 Apr; 27(2):142-150. PubMed ID: 30694914
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A; Marinelli D; Romeo U; Messineo D; De Felice F; De Vincentiis M; Valentini V; Mezi S; Valentini F; Vivona L; Chiavassa A; Cerbelli B; Santini D; Bossi P; Polimeni A; Marchetti P; Botticelli A
BMC Cancer; 2024 Apr; 24(1):430. PubMed ID: 38589857
[TBL] [Abstract][Full Text] [Related]
33. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Desilets A; Soulières D
Expert Opin Drug Saf; 2020 Aug; 19(8):927-934. PubMed ID: 32458764
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab in the first-line treatment of advanced head and neck cancer.
de Sousa LG; Ferrarotto R
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1321-1331. PubMed ID: 34689660
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
[TBL] [Abstract][Full Text] [Related]
36. PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.
Mo DC; Huang JF; Luo PH; Chen L; Zou B; Wang HL
Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):1-9. PubMed ID: 35907001
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for head and neck cancer: Recent advances and future directions.
Cramer JD; Burtness B; Ferris RL
Oral Oncol; 2019 Dec; 99():104460. PubMed ID: 31683169
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting].
Zech HB; Laban S; Schafhausen P; Bussmann L; Betz C; Busch CJ
HNO; 2019 Dec; 67(12):898-904. PubMed ID: 31701170
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S; Weiss J
Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]